NEW YORK, NY – Two prominent biotechnology companies, Vertex Pharmaceuticals and CRISPR Therapeutics, both led by Indian American CEOs, have been named to TIME’s 2025 list of the 100 Most Influential ...

Insiders were net buyers of Vertex, Inc.'s (NASDAQ:VERX ) stock during the past year. That is, insiders bought more stock than they sold. While insider transactions are not the most important thing ...

Vertex Pharma ceuticals CEO Reshma Kewalramani bought a big chunk of the biotech’s stock earlier this month. The move, her first open-market purchase in years, appears to be a show of confidence in ...

Your browser does not support the audio element. Vertex AI Workbench is a managed Jupyter environment in Google Cloud. It ships with native integration with BigQuery ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

Boston and London biotech company Vertex Pharmaceuticals is on a roll. In the past year and a half, Vertex worked with CRISPR Therapeutics to develop the first CRISPR treatment approved by the U.S.

The layoffs will heavily affect Vertex’s operations in Rhode Island, where the biotech will consolidate three facilities into one. The layoffs will heavily focus on the company’s Rhode Island ...

Vertex Pharmaceuticals reported disappointing Q1 revenue and earnings. The company also revealed it is temporarily pausing part of a phase 1/2 study of experimental cystic fibrosis drug VX-522. Vertex ...